Last reviewed · How we verify

NCT03978962

Performance and Safety of the Resorbable Collagen Membrane "Ez Cure"

Completed Last updated 4 February 2025
What this trial tests

trial testing Guided Tissue Regeneration in Oral Bone Defect in 56 participants. Completed in 26 August 2020.

Timeline
28 May 2019
Primary endpoint
26 August 2020
26 August 2020

Quick facts

Lead sponsorBiomatlante
StatusCompleted
Study typeOBSERVATIONAL
Enrollment56
Start date28 May 2019
Primary completion26 August 2020
Estimated completion26 August 2020
Sites2 locations across France

Drugs / interventions tested

Conditions studied

Sponsor

Biomatlante

Who can join

Adults 18 to 70, any sex, with Oral Bone Defect or Maxillofacial Bone Defect. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The evaluation of the clinical data has demonstrated the conformity of the Resorbable Collagen Membrane (RCM), EZ CureTM, with the relevant essential requirements for its use in periodontal applications. The RCM is intended for Guided Tissue Regeneration (GTR) and Guided Bone Regeneration (GBR) procedures. It acts as a barrier against the migration of epithelial cells within the bone defect (performance) and thus complies with several surgical indications in the treatment of maxillofacial bone defects. It has been concluded that the risks associated with the use of this device are acceptable when weighted against the benefits to the patients. In order to improve the clinical data on the RCM, the manufacturer, Biomatlante, decided to assess that the performance and safety of the device are maintained until the reaching of its intended use. In this objective, the goal of this study will be to observe the following parameters: 1. Tissue regeneration (mucosa health on the site of implantation) 2. Safety (report of any adverse event) 3. Radiographic analysis of periodontal tissues

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Guided Tissue Regeneration

Trials testing the same drug.

Other Biomatlante trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03978962.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing